Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 18, Issue 12, 2011, Pages 3384-3390

  Patel, Sameer H ^a   Kneuertz, Peter J ^a   Delgado, Maria ^a   Kooby, David A ^a   Staley III, Charles A ^a   El Rayes, Bassel F ^a   Kauh, John S ^a   Sarmiento, Juan M ^a   Hanish, Steven ^a   Cohen, Cynthia ^a   Farris III, Alton B ^a   Maithel, Shishir K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 83055181566     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1775-3     Document Type: Article

References (24)

1. American Cancer Society. Global cancer facts and figures, 2007. Atlanta: American Cancer Society; 2007.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-43.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
4. Kooby DA, Egnatashvili V, Graiser M, et al. Changing management and outcome of hepatocellular carcinoma: evaluation of 501 patients treated at a single comprehensive center. J Surg Oncol. 2008;98:81-8.
5. Oseini AM, Roberts LR. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets. 2009;13:443-54.
6. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80:550-60.
7. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001;233:227-35.
8. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007;72(Suppl 1): 30):30-44.
9. Torimura T, Sata M, Ueno T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 1998;29:986-91.
10. Li XM, Tang ZY, Zhou G, et al. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res. 1998;17:13-7.
11. Nakamura K, Zen Y, Sato Y, et al. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol. 2007;38:1532-46.
12. Aucejo F, Kim R, Zein N, et al. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl. 2009;15:169-76.
13. Zhang T, Sun HC, Xu Y, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res. 2005;11:8557-63.
14. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-74.
15. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
16. Yau T, Pang R, Chan P, Poon RT. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opin Pharmacother. 2010;11:2187-98.
17. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10:794-800.
18. Koeberle D, Montemurro M, Samaras P, et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15:285-92.
19. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
20. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027-35.
21. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
22. Limquiaco JL, Wong GL, Wong VW, et al. Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:63-9.
23. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240:900-9.
24. Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Invest Drugs. 2004;13:1555-68.